ASCO 2015 Highlights

Chairpersons of the various National Comprehensive Cancer Network (NCCN) tumor panels presented clinical practice updates at the recent 16th Annual Conference of the NCCN. Key updates, and relevant discussions, are highlighted.

Applying its priority review route, the FDA approved the biologic medication ipilimumab (Yervoy; Bristol-Myers Squibb) as a second-line therapy for the treatment of patients with unresectable or metastatic melanoma.

Interview with Al B. Benson, III, MD, FACP